Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. cut its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 45.6% during the third quarter, Holdings Channel reports. The institutional investor owned 7,497 shares of the company’s stock after selling 6,274 shares during the period. Principal Financial Group Inc.’s holdings in Dyne Therapeutics were worth $269,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. AQR Capital Management LLC boosted its position in shares of Dyne Therapeutics by 4.3% in the 2nd quarter. AQR Capital Management LLC now owns 8,495 shares of the company’s stock valued at $300,000 after purchasing an additional 352 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after purchasing an additional 709 shares during the last quarter. KBC Group NV boosted its stake in shares of Dyne Therapeutics by 53.4% during the 3rd quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares during the last quarter. Amalgamated Bank grew its position in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock valued at $99,000 after purchasing an additional 796 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in Dyne Therapeutics in the third quarter valued at approximately $34,000. 96.68% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Dyne Therapeutics

In other news, SVP Richard William Scalzo sold 1,455 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $40,914.60. Following the completion of the sale, the senior vice president now owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This trade represents a 1.13 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dirk Kersten sold 23,671 shares of the business’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $35.35, for a total value of $836,769.85. Following the completion of the transaction, the director now directly owns 99,652 shares in the company, valued at approximately $3,522,698.20. This represents a 19.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 44,742 shares of company stock worth $1,443,246 over the last three months. 20.77% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Raymond James raised shares of Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Chardan Capital reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $43.00 to $35.00 in a research report on Thursday, October 24th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $49.91.

Dyne Therapeutics Trading Down 0.8 %

Shares of NASDAQ:DYN opened at $24.57 on Tuesday. Dyne Therapeutics, Inc. has a 1 year low of $15.22 and a 1 year high of $47.45. The business has a fifty day simple moving average of $27.66 and a 200 day simple moving average of $34.39. The firm has a market cap of $2.50 billion, a price-to-earnings ratio of -6.90 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.